Purchase this article with an account.
Samuel K. Houston, Timothy G. Murray, Christina L. Decatur, Yolanda Pina, Ludimila Cavalcante, Theodore Lampidis; Use of 2-fluorodeoxy-d-glucose (2-FDG) to Target the Chemoresistant, Hypoxic Cell Population in Advanced LHBetaTAg Retinal Tumors. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2487.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The aim of the current study is to assess the impact of 2-fluorodeoxy-D-glucose (2-FDG) on tumor burden and hypoxia in the LHBETATAG retinal tumors.
The study protocol was approved by the University of Miami Institutional Animal Care and Use Review Board Committee and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. 17-week old (n=54) LHBETATAG transgenic mice were treated with 2-fluorodeoxy-D-glucose or saline control. These animals received one of three different treatments: (1) one injection of 2-FDG and sacrificed at one day post-treatment, (2) one injection of 2-FDG and sacrificed at one week post-treatment, or (3) 6 injections of 2-FDG (twice weekly injections repeated for three weeks) and sacrificed at one day post-last injection. At the time of enucleation, eye samples were snap frozen and analyzed for tumor burden and hypoxia using immunohistochemical techniques. Average densities of the different groups were statistically analyzed using ANOVA analysis. Results were considered significant if p≤ 0.05.
There was no apparent toxicity associated with 2-fluorodeoxy-D-glucose treatment. There was a significant reduction in tumor burden following treatment with 2-FDG at 1 day (86%) and 3 weeks (63%) post-treatment (p≤0.05). There was no reduction of tumor burden observed when mice were treated with 1 injection and eyes harvested at 1 week post-treatment (2%, p=0.0640). There was a significant reduction in hypoxic areas following treatment with 2-FDG at 1 day (100%) and 3 weeks (75%) post-treatment (p≤0.05).
2-fluorodeoxy-D-glucose (2-FDG) significantly reduces tumor burden and tumor hypoxia following a single injection, with continued efficacy following repeated injections for 3 weeks. 2-FDG treatment is efficacious in murine retinoblastoma tumors and may enhance tumor control when combined with other therapies. 2-FDG appears to target hypoxic cells, a population that has been resistant to chemotherapy and radiation. Of interest, 2-FDG is readily available and commonly used in medical imaging and has minimal known toxicities.
This PDF is available to Subscribers Only